SillaJen to Conduct Small-Scale Merger with Woosung Pharmaceutical

On April 24, SillaJen announced that it will merge with its subsidiary, Woosung Pharmaceutical, through an absorption-type merger. The company explained that the decision was made to "enhance management efficiency and create synergy." The merger will be conducted as a small-scale merger. SillaJen will remain as the surviving company, while Woosung Pharmaceutical will be dissolved after the merger. The merger ratio between SillaJen and Woosung Pharmaceutical is 1 to 0, and no new shares will be issued upon the merger. The effective date of the merger is July 1, 2025.